Cyclodextrin-based polymers for therapeutics delivery
AssigneeInsert Therapeutics, Inc.
InventorsMark E. Davis, Jungyeon Hwang, Tianyi Ke, Ching-Jou Lim, Thomas Schluep
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein.
Claims6
A polymer conjugate, comprising a therapeutic agent covalently attached to a polymer through a tether, wherein the tether comprises a self-cyclizing moiety.
A compound represented by Formula C:
- wherein
- P represents a polymer chain;
- CD represents a cyclic moiety;
- L1, L2 and L3, independently for each occurrence, may be absent or represent a linker group, provided that a plurality of occurrences of L2 represent linkers that are cleavable under biological conditions;
- D, independently for each occurrence, is selected from etoposide, tubulysin, epothilone, or an analog or derivative thereof;
- T, independently for each occurrence, represents a targeting ligand or precursor thereof;
- a, m and v, independently for each occurrence, represent integers in the range of 1 to 10;
- n and w, independently for each occurrence, represent an integer in the range of 0 to about 30,000;
- and
- b represents an integer in the range of I to about 30,000;
- and
- wherein either P comprises cyclodextrin moieties in the polymer chain or n is at least 1.
A compound represented by Formula C:
- wherein
- P represents a polymer chain;
- CD represents a cyclodextrin moiety;
- L2 independently for each occurrence, may be absent or represents a linker group, wherein for one or more occurrences, L2 is a linker group that comprises a phosphate group;
- L1 and L3, independently for each occurrence, may be absent or represent a linker group;
- D, independently for each occurrence, represents a therapeutic agent or a prodrug thereof;
- T, independently for each occurrence, represents a targeting ligand or precursor thereof;
- a, m and v, independently for each occurrence, represent integers in the range of 1 to 10;
- n and w, independently for each occurrence, represent an integer in the range of 0 to about 30,000;
- and
- b represents an integer in the range of I to about 30,000;
- and
- wherein either P comprises cyclodextrin moieties in the polymer chain or n is at least 1, and
- wherein a plurality of therapeutic agents or prodrugs thereof are covalently attached to the polymer chain through attachments that are cleavable.
Dependencies are inferred from the claim text.